HumanOptics AG develops, manufactures, and sells intraocular implantable solutions.
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has HumanOptics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: H9O1's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: H9O1 underperformed the German Medical Equipment industry which returned 21.6% over the past year.
Return vs Market: H9O1 underperformed the German Market which returned 8.1% over the past year.
Price Volatility Vs. Market
How volatile is HumanOptics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StShareholders Are Raving About How The HumanOptics (FRA:H9O1) Share Price Increased 313%
1 year ago | Simply Wall StHumanOptics (FRA:H9O1) Shareholders Have Enjoyed A Whopping 400% Share Price Gain
1 year ago | Simply Wall StHow Financially Strong Is HumanOptics AG (FRA:H9O1)?
Is HumanOptics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate H9O1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate H9O1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: H9O1 is unprofitable, so we can't compare its PE Ratio to the DE Medical Equipment industry average.
PE vs Market: H9O1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate H9O1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: H9O1 is overvalued based on its PB Ratio (14.8x) compared to the DE Medical Equipment industry average (4.8x).
How is HumanOptics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HumanOptics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of H9O1’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- HumanOptics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has HumanOptics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: H9O1 is currently unprofitable.
Growing Profit Margin: H9O1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: H9O1 is unprofitable, and losses have increased over the past 5 years at a rate of 52.5% per year.
Accelerating Growth: Unable to compare H9O1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: H9O1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.6%).
Return on Equity
High ROE: H9O1 has a negative Return on Equity (-77.17%), as it is currently unprofitable.
How is HumanOptics's financial position?
Financial Position Analysis
Short Term Liabilities: H9O1's short term assets (€6.0M) exceed its short term liabilities (€4.3M).
Long Term Liabilities: H9O1's short term assets (€6.0M) exceed its long term liabilities (€3.7M).
Debt to Equity History and Analysis
Debt Level: H9O1's debt to equity ratio (292.5%) is considered high.
Reducing Debt: H9O1's debt to equity ratio has increased from 113.7% to 292.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if H9O1 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if H9O1 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is HumanOptics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate H9O1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate H9O1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if H9O1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if H9O1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of H9O1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ms. Diana Bachmann serves as Vice President of Finance & Administration at HumanOptics AG and also serves as its Member of Management Board since May 01, 2020. She has been the Chief Executive Officer and ...
|Member of Supervisory Board||no data||no data||no data|
|Member of Supervisory Board||0.58yr||no data||no data|
|Chairman of Supervisory Board||0.58yr||no data||no data|
|Vice Chairman of Supervisory Board||0.58yr||no data||no data|
|Member of Supervisory Board||0.58yr||no data||no data|
Experienced Board: H9O1's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.9%.
HumanOptics AG's company bio, employee growth, exchange listings and data sources
- Name: HumanOptics AG
- Ticker: H9O1
- Exchange: DB
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: €33.304m
- Shares outstanding: 3.49m
- Website: https://www.humanoptics.com
Number of Employees
- HumanOptics AG
- Spardorfer Str. 150
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|H9O1||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jul 2006|
HumanOptics AG develops, manufactures, and sells intraocular implantable solutions. The company offers artificial intraocular lenses. It also provides CUSTOMFLEX ARTIFICIALIRIS, an iris prosthesis, which i ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/05 20:49|
|End of Day Share Price||2020/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.